COMPASS Pathways plc (CMPS)
Develops psilocybin-based therapy treatments for depression and PTSD.
$10.85-0.04%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+150.0%
The outlook
CMPS is trading near the midpoint of its 52-week range with strong analyst backing—the consensus leans "Strong Buy" across 16 analysts, and the average price target sits roughly 119% above the current price. Price momentum shows mixed signals against its moving averages, though the overall lean remains bullish based on analyst sentiment and valuation metrics.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 16 analysts
Price trendMixed vs its moving averages
52-week range60% of the way from its 52-week low to high
Price targetAvg target +119% vs current price
Analyst price target
~12-month · 16 analysts$23.75average target+118.9% vs now
Now $10.85
Low $13.00High $70.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.46B
52-wk high
$15.40
52-wk low
$3.92
50-day avg
$12.39
200-day avg
$8.14
Trailing P/E
—